Table 6 Cox proportional hazards analysis for predictors of BCSS in luminal BC validation set: effect of Ki-67LI, MS, tumor grade, HER2 status, PR status, and adjuvant therapy

Ki-67LI

0.006

0.003

   Low

   Moderate

0.020

2.016 (1.118-3.636)

0.211

1.359 (0.840-2.198)

   High

0.002

3.002 (1.522-5.923)

0.002

2.504 (1.410-4.448)

Tumor grade

0.031

0.021

   1

   2

0.018

1.696 (0.783-3.672)

0.055

1.817 (0.987-3.346)

   3

0.023

1.736 (0.634-4.753)

0.011

1.556 (0.986-3.659)

HER2 status

0.021

1.528 (1.022-2.385)

0.042

1.263 (0.982-2.746)

Mitosis scores

0.018

0.044

   1

   2

0.043

1.267 (0.651-2.466)

0.013

1.292 (0.742-2.257)

   3

0.086

2.113 (0.899-4.967)

0.017

1.877 (0.881-3.999)

PR status

0.030

0.635 (0.422-0.956)

0.064

0.701 (0.481-1.021)

Endocrine therapy (No/Yes)

0.886

0.992 (0.890-1.106)

0.314

1.049 (0.955-1.152)

Chemotherapy (No/Yes)

0.332

0.768 (0.451-0.309)

0.640

0.893 (0.557-1.432)